Truist lowered the firm’s price target on Boston Scientific (BSX) to $113 from $120 and keeps a Buy rating on the shares as part of a broad ...

Despite a shaky quarter due to U.S.-China trade tensions and a 6% dip in stock price, Boston Scientific still flexed its ...

Boston Scientific (NYSE:BSX) experienced a 6% decline in stock price over the last quarter, amid a period of market uncertainty driven by new tariffs imposed by the U.S. and retaliatory measures from ...

Cartesian Therapeutics Inc. followed up December’s phase IIb data with more good news regarding Descartes-08, offering 12-month efficacy and safety results that whetted Wall Street’s appetite for the ...

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance cardiac cryoablation system in treating ...